يعرض 1 - 20 نتائج من 40 نتيجة بحث عن '"рандомизированные контролируемые исследования"', وقت الاستعلام: 0.45s تنقيح النتائج
  1. 1
    Academic Journal
  2. 2
    Academic Journal

    المصدر: Rational Pharmacotherapy in Cardiology; Vol 12, No 6 (2016); 31-39 ; Рациональная Фармакотерапия в Кардиологии; Vol 12, No 6 (2016); 31-39 ; 2225-3653 ; 1819-6446 ; 10.20996/1819-6446-2016-12-6

    وصف الملف: application/pdf

    Relation: https://www.rpcardio.com/jour/article/view/1192/1220; Savelyev VS, Chazov EI, Gusev EI, et al. The Russian clinical recommendations for diagnosis, treatment and prevention of venous thromboembolic events. Flebologiia 2010; 4: 1-40. In Russian (Савельев В.С., Чазов Е.И. Гусев Е.И. и др. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений. Флебология 2010; 4: 1-40).; Heit J., Cohen A., Anderson F. et al. Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. Blood (ASH Annual Meeting Abstracts) 2005; 106: Abstract 910.; Cohen A., Agnelli G., Anderson F. et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007; 98: 756-64.; Spencer F., Emery C., Lessard D. et al. The Worcester Venous Thromboembolism study: a populationbased study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med 2006; 21: 722-7.; Cohen A., Dobromirski M. The use of rivaroxaban for short- and long-term treatment of venous thromboembolism. Thromb Haemost 2012; 107 (6): 1035-43.; Guidelines on the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology, 2014; Kearon C., Akl E., Comerota A. et al. Antithrombotic Therapy for VTE Disease Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (Suppl 2): S419-94.; Ansell J., Hirsh J., Hylek E. et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th ed). Chest 2008; 133: S160-98.; Moher D., Liberati A., Tetzlaff J., Altman D.G. The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Open Med 2009; 3: 123-30.; Lau J., Ioannidis J.P., Schmid C.H. Quantitative synthesis in systematic reviews. Ann Intern Med 1997; 127: 820-6.; Mantel N., Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-48.; DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.; Higgins J.P., Thompson S.G. Quantifying heterogeneity in a metaanalysis. Stat Med 2002; 21: 1539- 58.; The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-510.; The EINSTEIN-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012;366:1287-97.; Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342-52.; Schulman S, Kakkar AK, Goldhaber SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014;129:764-72.; Agnelli G., Buller H.R., Cohen A., et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369 (9): 799-808.; Prins MH, Lensing AW, Bauersachs R, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal 2013; 11:21.; https://www.rpcardio.com/jour/article/view/1192

  3. 3
    Academic Journal

    المصدر: Rational Pharmacotherapy in Cardiology; Vol 17, No 2 (2021); 249-255 ; Рациональная Фармакотерапия в Кардиологии; Vol 17, No 2 (2021); 249-255 ; 2225-3653 ; 1819-6446

    وصف الملف: application/pdf

    Relation: https://www.rpcardio.com/jour/article/view/2433/2146; https://www.rpcardio.com/jour/article/view/2433/2164; Jaillon P. L'essai Clinique controle randomise [Controlled randomized clinical trials]. Bull Acad Natl Med. 2007;191:739-56; discussion 756-758.; Pocock S, Elbourne D. Randomised trials or observational studies? Lancet. 2000;342:1907-9.; Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000;342(25):1887-92. DOI:10.1056/NEJM200006223422507.; Lang GF. Diseases of the circulatory system. Moscow: Gosudarstvennoye izdatel'stvo meditsinskoy lit-eratury; 1957 (In Russ.) [Ланг Г.Ф. Болезни системы кровообращения. М.: Государственное издательство медицинской литературы; 1957].; Echt DS, Liebeson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, fle- cainide, or placebo: The Cardiac Arrhythmia Supression Trial. N Engl J Med. 1991;324:781-8.; Roelins M. De testimonio: on the evidence for decisions about the use of therapeutic interventions. Clinical Medicine. 2008;8(6):579-88.; Streptomycin treatment of pulmonary tuberculosis: a Medical Research Council investigation. BMJ. 1948;2:769-82. DOI:10.1136/bmj.2.4582.769.; Glasziou P, Chalmers I, Rawlins M, et al. When are randomized trials unnecessary? Picking signal from noise. BMJ. 2007;334:349-51.; Storm B. The use of pharmacoepidemiology to study beneficial drug effects. In: Strom B.L., Kimmel S.E., Hennessy S., eds. Textbook of pharmacoepidemiology. Philadelphia: Wiley-Blackwell; 2006. P.321-331.; Portioli I. I limited degli studi clinici controllata: il caso della reumatologia [The limits of controlled clinical studies: the case of rheumatology]. Ann Ital Med Int. 2000;15(1):39-46.; Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med. 2000;342(25):1878-86. DOI:10.1056/NEJM200006223422506.; Penston J. Statistics-based research - a pig in a poke? J EvalClin Pract. 2011;17(5):862-7. DOI:10.1111/j.1365-2753.2011.01717.x.; Packer M, McMurray JJ, Desai AS, et al. PARADIGM-HF Investigators and Coordinators. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015;131(1):54-61. DOI:10.1161/CIRCULATION-AHA.114.013748.; Colditz GA. Overview of the epidemiology methods and applications: strengths and limitations of observational study designs. Crit Rev Food Sci Nutr. 2010;50Suppl 1(s1):10-12. DOI:10.1080/10408398.2010.526838.; Abel U, Koch A. The role of randomization in clinical studies: myths and beliefs. J Clin Epidemiol. 1999;52(6):487-97. DOI:10.1016/s0895-4356(99)00041-4.; Guerrera F Renaud S, Tabbo F, et al. How to design a randomized clinical trial: tips and tricks for conduct a successful study in thoracic disease domain. J Thorac Dis. 2017;9(8):2692-6. DOI:10.21037/jtd.2017.06.147.; Glynn RJ, Schneeweiss S, Sturmer T. Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol. 2006;98:253-9. DOI:10.1111/j.1742-7843.2006.pto_293.x.; Марцевич С.Ю., Кутишенко Н.П., Лукина Ю.В., и др. Наблюдательные исследования и регистры. Их качество и роль в современной доказательной медицине. Кардиоваскулярная Терапия и Профилактика. 2021;20(2):61-6. DOI:10.15829/1728-8800-2021-2786.; Singal AG, Higgins PDR, Waijee AK. A primer on effectiveness and efficacy trials. Clinical and Translation Gastroenterology. 2014;5:e45. DOI:10.1038/ctg.2013.13.; Normand SLT, Sykora K, Li P, et al. Reader's guide to critical appraisal of cohort studies: 3. Analytical strategies to reduce confounding. BMJ. 2005;330:1021-3. DOI:10.1136/bmj.330.7498.1021.; Марцевич С.Ю., Лукина Ю.В., Кутишенко Н.П., и др. Наблюдательное многоцентровое исследование применения никорандила у больных стабильной ишемической болезнью сердца с высоким сердечно-сосудистым риском (НИКЕЯ): дизайн, первые результаты. Российский Кардиологический Журнал. 2017;(9):75-82. DOI:10.15829/1560-4071-2017-9-75-82; Марцевич СЮ., Лукина Ю.В., Кутишенко Н.П., и др. Особенности и основные проблемы лечения статинами пациентов высокого и очень высокого сердечнососудистого риска в условиях реальной клинической практики (по данным наблюдательного исследования “ПРИОРИТЕТ”). Кардиоваскулярная Терапия и Профилактика. 2018;17(6):52-61. DOI:10.15829/1728-8800-2018-6-52-61.; Марцевич С.Ю., Лукина Ю.В., Кутишенко Н.П., и др. Приверженность к приему новых оральных антикоагулянтов у пациентов с фибрилляцией предсердий в реальной клинической практике (результаты исследования АНТЕЙ). Рациональная Фармакотерапия в Кардиологии. 2019;15(6):864-872. DOI:10.20996/1819-6446-2019-15-6-864-872.; Лукина Ю.В., Кутишенко Н.П., Марцевич С.Ю. Эффективность, безопасность и отдаленные исходы применения никорандила у больных стабильной ишемической болезнью сердца по данным рандомизированного и наблюдательного исследований. Рациональная Фармакотерапия в Кардиологии. 2019;15(5):641-8. DOI:10.20996/1819-6446-2019-15-5-641-648.; Марцевич С.Ю., Лукина Ю.В., Кутишенко Н.П., и др. Приверженность к терапии статинами пациентов высокого и очень высокого сердечно-сосудистого риска в условиях реальной клинической практики: диагностика и возможные пути решения проблемы (по данным наблюдательного исследования ПРИОРИТЕТ). Рациональная Фармакотерапия в Кардиологии. 2018;14(6):891-900. DOI:10.20996/1819-6446-2018-14-6-891-900.; Zhang Z, Peluso MJ, Gross CP, et al. Adherence reporting in randomized controlled trials. Clin Trials. 2014;(2):195-204. DOI:10.1177/1740774513512565.; Федеральный закон "Об обращении лекарственных средств" от 12.04.2010 N 61-ФЗ. Доступен на: http://pravo.gov.ru/proxy/ips/?docbody=&nd=102137440.; https://www.rpcardio.com/jour/article/view/2433

  4. 4
    Academic Journal

    المصدر: Annals of the Russian academy of medical sciences; Vol 74, No 2 (2019); 125-135 ; Вестник Российской академии медицинских наук; Vol 74, No 2 (2019); 125-135 ; 2414-3545 ; 0869-6047 ; 10.17816/PTORS742

    وصف الملف: application/pdf

  5. 5
    Academic Journal

    المصدر: Медицинский совет, Vol 0, Iss 14, Pp 114-118 (2015)

    وصف الملف: electronic resource

  6. 6
    Academic Journal
  7. 7
    Academic Journal

    المصدر: Traumatology and Orthopedics of Russia; Vol 24, No 4 (2018); 137-147 ; Травматология и ортопедия России; Vol 24, No 4 (2018); 137-147 ; 2542-0933 ; 2311-2905 ; 10.21823/2311-2905-2018-24-4

    وصف الملف: application/pdf

  8. 8
    Academic Journal
  9. 9
    Academic Journal

    المصدر: Rational Pharmacotherapy in Cardiology; Vol 12, No 5 (2016); 567-573 ; Рациональная Фармакотерапия в Кардиологии; Vol 12, No 5 (2016); 567-573 ; 2225-3653 ; 1819-6446 ; 10.20996/1819-6446-2016-12-5

    وصف الملف: application/pdf

    Relation: https://www.rpcardio.com/jour/article/view/1338/1381; Lang GF. Diseases of the circulatory system. Moscow: Medgiz; 1957. (In Russian) [Ланг Г.Ф. Болезни системы кровообращения. М.: Медгиз; 1957].; Есht DS, Liebeson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: The Cardiac Arrhythmia Supression Trial. N Engl J Med. 1991; 324: 781-8. doi:10.1056/NEJM199103213241201.; Harris M, Taylor G, Jackson D. Clinical evidence made easy. Hockley, Essex: Scion Publishing Ltd; 2014.; Wang D, Bakhai A, eds. Clinical trials. A practical guide to design, analysis and reporting. London: Remedica Publishing; 2006.; Bønaa KH, Mannsverk J, Wiseth R, et al. Drug-Eluting or Bare-Metal Stents for Coronary Artery Disease. N Engl J Med. doi:10.1056/NEJMoa1607991.; ISIS-4 (Fourth International Study of Infarct Survival) Collaborative. A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction. Lancet. 1995; 345: 669-85.; MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999; 353: 2001–07. doi:10.1016/S0140-6736(99)04440-2.; Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation. 1999;100:2312-8. doi:10.1161/01.CIR.100.23.2312.; Walker AM, Stampfer MJ. Observational studies of drug safety. Lancet. 1996; 348: 489. doi:10.1016/S0140-6736(05)64664-8.; Connolly SJ, Ezekowitz SJ, Ysuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361: 1139–51. doi:10.1056/NEJMoa0905561.; Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365:883-91. doi:10.1056/NEJMoa1009638.; Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92. doi:10.1056/NEJMoa1107039.; Rawlins M. De testimonio: on the evidence for decisions about the use of therapeutic interventions. Lancet. 2008; 372: 2152-61. doi:10.1016/S0140-6736(08)61930-3.; Glasziou P, Chalmers I, Rawlins M, McCulloch P. When are randomized trials unnecessary? Picking signal from noise. BMJ. 2007;334:349-51. doi:10.1136/bmj.39070.527986.68.; Glynn RJ, Schneeweiss S, Sturmer T. Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol. 2006; 98:253-9. doi:10.1111/j.1742-7843.2006.pto_293.x.; Normand SLT, Sykora K, Li P, et al. Aderson G.M. Readers guide to critical appraisal of cohort studies: 3. Analytical strategies to reduce confounding. BMJ. 2005; 330: 1021-3. doi:10.1136/bmj.330.7498.1021.; Larsen TB, Skjoth F, Nielsen PB, et al. Comparative effectiveness and safety of non-vitamin K antagonists oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted cohort study. BMJ. 2016;353:i3189. doi:10.1161/CIRCULATIONAHA.115.015710.; MacMahon M, Collins R. Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studies. Lancet. 2001;357:455-62. doi:10.1016/S0140- 6736(00)04017- 4.; Gliklich RE, Dreyer NA, eds. Registries for evaluating patient outcomes: a user’s guide. 2nd ed. Rockville: Agency for Healthcare Research and Quality (US); 2010.; Martsevich SY, Navasardyan AR, Zakharova NA, Lukyanov MM. New oral anticoagulants: whether the results of the international well-controlled studies with these drugs carry on Russian patients? Kardiovaskulyarnaya Terapiya i Profilaktika 2015; 14 (5): 48-52. (IN Russian) [Марцевич С.Ю., Навасардян А.Р., Захарова Н.А., Лукьянов М.М. Новые оральные антикоагулянты: можно ли результаты международных контролируемых исследований с этими препаратами переносить на российских больных? Кардиоваскулярная Терапия и Профилактика 2015; 14(5): 48-52].; Bangalore S, Steg PG, Deedwania P, et al. β-Blocker Use and Clinical Outcomes in Stable Outpatients With and Without Coronary Artery Disease. JAMA. 2012;308:1340-9. doi:10.1001/jama.2012.12559.; Collins R, MacMahon M. Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials. Lancet. 2001; 357: 373-80. doi:10.1016/S0140- 6736(00)03651-5.; https://www.rpcardio.com/jour/article/view/1338

  10. 10
    Academic Journal

    المصدر: Rational Pharmacotherapy in Cardiology; Vol 12, No 1 (2016); 31-39 ; Рациональная Фармакотерапия в Кардиологии; Vol 12, No 1 (2016); 31-39 ; 2225-3653 ; 1819-6446 ; 10.20996/1819-6446-2016-12-1

    وصف الملف: application/pdf

    Relation: https://www.rpcardio.com/jour/article/view/1193/1221; Savelyev VS, Chazov EI, Gusev EI, et al. The Russian clinical recommendations for diagnosis, treatment and prevention of venous thromboembolic events. Flebologiia 2010; 4: 1-40. In Russian (Савельев В.С., Чазов Е.И. Гусев Е.И. и др. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений. Флебология 2010; 4: 1-40).; Heit J., Cohen A., Anderson F. et al. Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. Blood (ASH Annual Meeting Abstracts) 2005; 106: Abstract 910.; Cohen A., Agnelli G., Anderson F. et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007; 98: 756-64.; Spencer F., Emery C., Lessard D. et al. The Worcester Venous Thromboembolism study: a populationbased study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med 2006; 21: 722-7.; Cohen A., Dobromirski M. The use of rivaroxaban for short- and long-term treatment of venous thromboembolism. Thromb Haemost 2012; 107 (6): 1035-43.; Guidelines on the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology, 2014; Kearon C., Akl E., Comerota A. et al. Antithrombotic Therapy for VTE Disease Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (Suppl 2): S419-94.; Ansell J., Hirsh J., Hylek E. et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th ed). Chest 2008; 133: S160-98.; Moher D., Liberati A., Tetzlaff J., Altman D.G. The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Open Med 2009; 3: 123-30.; Lau J., Ioannidis J.P., Schmid C.H. Quantitative synthesis in systematic reviews. Ann Intern Med 1997; 127: 820-6.; Mantel N., Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-48.; DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.; Higgins J.P., Thompson S.G. Quantifying heterogeneity in a metaanalysis. Stat Med 2002; 21: 1539- 58.; The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-510.; The EINSTEIN-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012;366:1287-97.; Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342-52.; Schulman S, Kakkar AK, Goldhaber SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014;129:764-72.; Agnelli G., Buller H.R., Cohen A., et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369 (9): 799-808.; Prins MH, Lensing AW, Bauersachs R, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal 2013; 11:21.; https://www.rpcardio.com/jour/article/view/1193

  11. 11
    Academic Journal

    المصدر: Rational Pharmacotherapy in Cardiology; Vol 4, No 4 (2008); 76-79 ; Рациональная Фармакотерапия в Кардиологии; Vol 4, No 4 (2008); 76-79 ; 2225-3653 ; 1819-6446 ; 10.20996/1819-6446-2008-4-4

    وصف الملف: application/pdf

    Relation: https://www.rpcardio.com/jour/article/view/1142/1179; Veterans Administration Co-operative Study Group. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 1967;202:1028-34.; Yusuf S., Peto R., Lewis J. et al. Beta-blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985;27:335-71.; Есht D.S., Liebeson P.R., Mitchell L.B. et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: The Cardiac Arrhythmia Supression Trial. N Engl J Med 1991;324(12):781-8.; The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342(3):145-53.; The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362(9386):782–8.; The PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351(20):2058- 68.; The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358(15):1547-59.; Wright J.T. Jr, Dunn J.K., Cutler J.A. et al. for the ALLHAT Collaborative Research Group. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA 2005;293(13):1595–608.; Dahlf B., Sever P.S., Poulter N.R. et al for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906.; Wald N., Law M. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003;326:1419-25.; Gaede P., Vedel P., Larsen N. et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348(5):383-93.; European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 2007;28(19):2375-414.; Марцевич С.Ю. Проблема лечения статинами в России: помогут ли дженерики? Рационал Фармакотер Кардиол 2006;(2):57-60.; Якусевич В.В. Качественное лекарственное средство: каким оно должно быть. Рационал Фармакотер Кардиол 2006;(4):41-6.; https://www.rpcardio.com/jour/article/view/1142

  12. 12
  13. 13
  14. 14
    Academic Journal

    المصدر: Rheumatology Science and Practice; Vol 53, No 5 (2015); 564-567 ; Научно-практическая ревматология; Vol 53, No 5 (2015); 564-567 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20155

    وصف الملف: application/pdf

    Relation: https://rsp.mediar-press.net/rsp/article/view/2134/1360; Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage. 2008;16:137–62. doi:10.1016/j.joca.2007.12.013; Vliet Vlieland TP, van den Ende CH. Nonpharmacological treatment of rheumatoid arthritis. Cur Opin Rheumatol. 2001;23(3):259–64. doi:10.1097/BOR.0b013e32834540fb; Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011;70:896–904. doi:10.1136/ard.2011.151027; Villamar MF, Contreras VS, Kuntz RE, Fregni F. The reporting of blinding in physical medicine and rehabilitation randomized controlled trials: a systematic review. J Rehabil Med. 2013;45(1):6–13. doi:10.2340/16501977-1071; Mayo NE, Goldberg MS. When is a case-control study not a case-control study? J Rehabil Med. 2009;41(4):209–16. doi:10.2340/16501977-0343; CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:869. doi: http://dx.doi.org/10.1136/bmj; Fregni F, Imamura M, Chien HF, et al. Challenges and recommendations for placebo controls in randomized trials in physical and rehabilitation medicine: a report of the international placebo symposium working group. Am J Phys Med Rehabil. 2010;89:160–172. doi:10.1097/PHM.0b013e3181bc0bbd; Witt CM, Aichin M, Cherkin D, et al. Effectiveness guidance document (EGD) for Chinese medicine trials: a consensus document. Trials. 2014 May 13;15:169. doi:10.1186/1745-6215-15-169; MacPherson H, White A, Cummings M, et al. Standards for reporting interventions in controlled trials of acupuncture: The STRICTA recommendations. STandards for Reporting Interventions in Controlled Trails of Acupuncture. Acupunct Med. 2002;20(1):22–5. doi:10.1136/aim.20.1.22; Fregni F, Boggio PS, Lima MC, et al. A sham-controlled, phase II trial of transcranial direct current stimulation for the treatment of central pain in traumatic spinal cord injury. Pain. 2006;122:197–209. doi:10.1016/j.pain.2006.02.023; Kaptchuk TJ, Stason WB, Davis RB. Sham device v inert pill: randomised controlled trial of two placebo treatments. BMJ. 2006;332: 391–7. doi:10.1136/bmj.38726.603310.55; Gandiga PC, Hummel FC, Cohen LG. Transcranial DC stimulation (tDCS): a tool for double-blind sham-controlled clinical studies in brain stimulation. Clin Neurophysiol. 2006;117:845–50. doi:10.1016/j.clinph.2005.12.003; Gerdesmeyer L, Frey C, Vester J, et al. Radial extracorporeal shock wave therapy is safe and effective in the treatment of chronic recalcitrant plantar fasciitis: results of a confirmatory randomized placebo-controlled multicenter study. Am J Sports Med. 2008;36:2100–09. doi:10.1177/0363546508324176; Witt CM, Aickin M, Baca T, et al. Effectiveness guidance document (EGD) for acupuncture research – a consensus document for conducting trials. Trials. 2014;15:169. doi:10.1186/1745-6215-15-169; Brosseau L, Casimiro L, Robinson V, et al. Therapeutic ultrasound for treating patellofemoral pain syndrome. Cochrane Database Syst Rev. 2001;(4):CD003375. doi:10.1002/14651858.cd003375; Vickers AJ, de Craen AJ. Why use placebos in clinical trials? A narrative review of the methodological literature. J Clin Epidemiol. 2000;53:157–61. doi:10.1016/S0895-4356(99)00139-0; Kaptchuk TJ, Goldman P, Stone DA, et al. Do medical devices have enhanced placebo effects? J Clin Epidemiol. 2000;53:786–92. doi:10.1016/S0895-4356(00)00206-7; Kaptchuk TJ. The placebo effect in alternative medicine: can the performance of a healing ritual have clinical significance? Ann Intern Med. 2002;136:817–25. doi:10.7326/0003-4819-136-11-200206040-00011; Khan A, Warner HA, Brown WA. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database. Arch Gen Psychiatry. 2000;57:311–7. doi:10.1001/archpsyc. 57.4.311; Langevin HM, Wayne PM, MacPherson H, et al. Paradoxes in acupuncture research: strategies for moving forward. Evidence- Based Complem Alternat Med. 2011;2011:Article ID 180805, 11 p. doi:10.1155/2011/180805; Spadaro A, De Luca T, Massimiani MP, et al. Occupational therapy in ankylosing spondylitis: Short-term prospective study in patients treated with anti-TNF-alpha drugs. Joint Bone Spine. 2008;75(1):29–33. doi:10.1016/j.jbspin.2007.07.006; Berezne A, Seror R, Morell-Dubois S, et al. Impact of systemic sclerosis on occupational and professional activity with attention to patients with digital ulcers. Arthritis Care Res (Hoboken). 2011;63(2):277–85. doi:10.1002/acr.20342; Targino RA, Imamura M, Kaziyama HH, et al. A randomized controlled trial of acupuncture added to usual treatment for fibromyalgia. J Rehabil Med. 2008;40: 582–8. doi:10.2340/16501977-0216; Дубинина ТВ, Подряднова МВ, Красненко СО, Эрдес ШФ. Лечебная физкультура при анкилозирующем спондилите: рекомендации и реальность. Научно-практическая ревматология. 2014;52(2):187–91 [Dubinina TV, Podryadnova MV, Krasnenko SO, Erdes ShF. Therapeutic exercise for patients with ankylosing spondylitis: recommendations and reality. Nauchnoprakticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(2):187–91 (In Russ.)]. doi:10.14412/1995- 4484-2014-187-191; https://rsp.mediar-press.net/rsp/article/view/2134

  15. 15
  16. 16
  17. 17
  18. 18
    Academic Journal
  19. 19
  20. 20